HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gillette

This article was originally published in The Rose Sheet

Executive Summary

Blades and Razors sales advanced 11% to $1.21 bil. on a reported basis, and profit from operations in the unit increased 16% to $488 mil. in the second quarter, Gillette announces Aug. 4. Results were boosted in part by a double-digit sales increase in North America for the Venus women's shaving brand, which benefited from the launch of Venus Vibrance and new Venus Disposable razor. Gillette's global value share of the blades/razors segment increased by more than one percentage point to 71.5%, while M3Power remained the top-selling men's razor in North America and worldwide with a 19% value share, according to the firm. Personal care sales were up 9% to $256 mil., with profit from operations advancing 25% to $30 mil., reflecting improved product mix and "ongoing trade-up from shaving foams to gels," company notes. Net sales rose 13.4% to $2.77 bil., while net income increased 16.9% to $498 mil...

You may also be interested in...



Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate

FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.

UsernamePublicRestriction

Register

RS013250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel